Abstract:
A textile gasket and method of construction thereof for establishing a seal between mating members in a high temperature application is provided. The gasket has a knit, tubular body constructed at least in part of non-metallic, heat-resistant yarns. The body extends between opposite ends with at least one of the ends being rolled toward the other end to form a circumferentially extending rolled portion of a predetermined diameter for receipt between the mating members.
Abstract:
The present invention relates to a method of inducing cancer cells into dormancy and treating cancer in a subject. This method involves administering to a subject an effective amount of a compound that disrupts interaction between urokinase plasminogen activator receptor and integrin, thereby incuding cancer cells into dormancy and treating cancer in the subject. Also disclosed is a method of disrupting interaction between integrin and urokinase plasminogen activator receptor on cancer cells. The present invention also relates to a method of screening for compounds effective in inducing tumor dormancy and treating cancer in a subject.
Abstract:
A continuous halogen-free flame-retardant filament and method of forming thereof includes providing MC, a phosphorus compound, and PET, and then, forming a mixture of the MC, phosphorus compound, and PET. And lastly, extruding the mixture to form the halogen-free flame-retardant filament. The filament can be braided, woven or knitted into a variety of fabric constructions, such as, for example, sleeves for protecting wires.
Abstract:
The present invention features compounds and pharmaceutical compositions comprising the same that are useful for modulating p53 activity. The invention further provides methods for inhibiting the biological activity of p53 and for treating diseases such as, for instance, cancer, cell death caused all or in part by cancer treatments such as chemotherapy or radiation thereapy, neuron cell death, stroke, Alzheimer's Disease and Parkinson's Disease.
Abstract:
The present invention features compounds and pharmaceutical compositions comprising the same that are useful for modulating p53 activity. The invention further provides methods for inhibiting the biological activity of p53 and for treating diseases such as, for instance, cancer, cell death caused all or in part by cancer treatments such as chemotherapy or radiation thereapy, neuron cell death, stroke, Alzheimer's Disease and Parkinson's Disease.
Abstract:
The present invention features compounds of the following general formula (I) wherein R 1 is selected from the group consisting of hydrogen, lower alkyl, aryl, aralkyl; substituted aralkyl, heteroaryl; substituted heteroaryl, phenyl, SO 2 , NH 2 , NO 2 , SO 2 , CH 2 , CH 2 CH 3 , OCH 3 , OCOCH 3 , CH 2 COCH 3 , and OH, CN and halogen; R 2 is selected from the group consisting of hydrogen; lower alkyl, aryl, phenyl, aralkyl; substituted aralkyl, heteroaryl; substituted heteroaryl, SO 2 NH 2 NH 3 + NO 2 , SO 2 , CH 3 , CH 2 CH 3 , OCH 3 , OCOCH 3 , CH 2 COCH 3, and OH, halogen, carboxy, and alkoxy; X is selected from the group consisting of lower alkyl, SO 2 , NH, NO 2 , , CH 3 , CH 2 CH 3 , OCH 3 , OCOCH 3 , CH 2 COCH 3 , and OH, carboxy, and alkoxy; and n is an integer from O to 10 and their pharmaceutically acceptable salts of acids or bases as well as pharmaceutical compositions comprising these compounds. The invention further provides methods for preventing or inhibiting the binding of bromodomains to acetyl-lysine residues of proteins and methods for treating HIV infection and HW related disease. The present invention also features compounds of the following general formula (II) wherein: R 1 R 2 and R 3 are independently selected from the group consisting of hydrogen; lower alkyl, aryl, phenyl, aralkyl; substituted aralkyl, heteroaryl; substituted heteroaryl, SO 2 , NH 2 , NH 3 + NO 2, SO 2 , CH 3 , CH 2 CH 3 , OCH 3 , OCOCH 3 , CH 2 COCH 3 , OH, SH, halogen, carboxy; and R 4 is selected from the group consisting of lower alkyl, aryl, SO 2 , NH, NO 2 , CH 3 , CH 2 CH 3 , OCH 3 , OCOCH 3 , CH 2 COCH 3 , OH, carboxy, and alkoxy as well as pharmaceutical compositions comprising these compounds. The invention further provides methods for preventing or inhibiting the binding of bromodomains to acetyl-lysine residues of proteins and methods f treating HW infection and HIY related disease. The present invention also features compounds of formula (III) wherein R 1 , R 2 , R 3 , R 4 R 5 , and R 6 are independently selected from the group consisting of hydrogen; lower alkyl, aryl, phenyl, aralkyl; substituted aralkyl, heteroaryl, substituted heteroaryl, SO 2 NH 2 , NH 3 + , NO 2 , SO 2 , CH 3 , CH 2 CH 3 , OCH 3 , OCOCH 3 , CH 2 COCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 COOH, OCHCH 3 COOH, OCH 2 COCH 3 , OCH 2 CONH 2 , OCOCH(CH 3 ) 2 , OCH 2 CH 2 OH, OCH 2 CH 2 CH 3 , O(CH 2 ) 3 CH 3 , OCHCH 3 COOCH 3 , OCH 2 CON(CH 3 ) 2 ,NH(CH 2 ) 3 N(CH 3 ) 2 , NH(CH 2 ) 2 N(CH 3 ) 2 , NH(CH 2 ) 2 OH, NH(CH 2 ) 3 CH 3 , NHCH 3 , SH, halogen, carboxy, and alkoxy as well as pharmaceutical compositions comprising these compounds. The invention further provides methods for preventing or inhibiting the binding of bromodomains to acetyl-lysine residues of proteins and methods for treating HIV infection and HIV related disease.
Abstract:
The present invention provides fragments of SNT and FGFR which can form a binding complex that is amenable to structural determinations by NMR spectroscopy. The three-dimensional structural data is also included as part of the invention. In addition, the present invention provides methodology for related structure based rational drug design using the three-dimensional data. Nucleotide and amino acid sequences of the fragments are also provided.
Abstract:
A one-component epoxy composition containing a latent catalyst and with surprisingly long storage stability. The catalyst being a reaction product of at least one tertiary amine compound and at least one polymer having at least one carboxylic acid and/or anhydride group.
Abstract:
This disclosure relates generally to compounds and compositions comprising one or more diphenylethylene, diphenylethylyne, and azobenzene analogs. These compounds are useful for treating diseases associated with NF-kB and p53 activity, such as cancer and inflammatory disease.
Abstract:
A zero-halogen flame-retardant compound and continuous materials extruded therefrom comprise poly(ethylene terephthalate) (PET), fire-retardant ingredients melamine cyanurate (MC) and melamine polyphosphate (MPP), and an organo titanate coupling agent. The coupling agent acts as a dispersion agent to the fine powders of PET, MC and MPP and also allows the resin of the fine powders to be compounded at a reduced temperature which prevents degradation of the PET. The compound can be extruded as a thin film, sheet or tubing, and also as a filament or yarn, including monofi laments and multifi laments, which can ultimately be used to construct a protective sleeve.